Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

NeOnc Technologies Holdings, Inc. - Common Stock (NQ:NTHI)

7.415 +0.435 (+6.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NeOnc Technologies Holdings, Inc. - Common Stock

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
New to The Street's Esteemed Client NeOnc Technologies Finalizes $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation
Via ACCESS Newswire
NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
New to The Street Signs NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) to 12-Part National Broadcast Series Including T.V. Network Features, Earned Media, Commercials, and Iconic Outdoor Billboards
Via ACCESS Newswire
NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar Investment
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies to Participate at the BTIG Virtual Biotechnology Conference
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — Today at 11:00 a.m. ET
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Executes Sub-License Agreement, Marking Key Milestone Toward Closing $50 Million Strategic Partnership with Quazar Investment
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership with Quazar Investment
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Holdings, Inc. Joins Russell Microcap® Index
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New President
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.